**PARIS** 17-20 SEPT 2025

M. Rodeghiero<sup>1</sup>, C. Boudet<sup>2</sup>, G. Doat<sup>2</sup>, MD. Thouvenin<sup>1</sup> 1. R&D Department, Pierre-Fabre Dermo-Cosmetics & Personal Care, Toulouse, France

### INTRODUCTION

- Emollients are considered as the first-line therapy of atopic dermatitis management. Their prolonged application has been shown to improve skin condition, patient's quality of life and space-out flareups. These products must be safe, effective and suitable for infants, children and adults.
- This study aimed to assess the tolerance and efficacy of a new emollient Plus (balm) containing Aquaphilus Dolomiae Dextran sodium sulfate extracts, intended to improve long-term atopic skin condition.

# MATERIAL AND METHODS

66 Subjects from 5 months to 56 years old were included in a 6-months-long (168 days) open clinical study. They applied the product twice a day on face & body.

2. Medical Department, Eau Thermale AVENE, Les Cauquillous, Lavaur, France

#### Main inclusion criteria:

- Mild AD with SCORAD between 10 and 25
- Xerosis intensity ≥ 2 (scale 0-3) & pruritus intensity ≥ 3 (NRS scale 0-10)
- At least one peak of xerosis and pruritus per month reported by the subjects/parents during the 3 previous months.

#### **Assessments:**

- AD severity (SCORAD index) including xerosis and pruritus
- Quality of life (Dermatology Life Quality Index for adults, children and infants; DLQI, CDLQI, IDQOL)
- Number of peaks of xerosis and pruritus
- Tolerance
- Cosmetic acceptability.

## **EFFICACY**

#### Significant improvement of clinical parameters and quality of life at each timepoint: \*p<0.05 vs D1 \*\*p<0.001 vs D1 **PRURITUS SCORAD INDEX XEROSIS** 25 22,7 -50% 20 **-77% -49%** 11,4 -79% Mean St -62% \*\* \*\* -94% Mean \*\* -85% \*\* 5,2 \*\* **-96**% 0,4 0,1 0,6 0,2 D29 D85 D169 D85 D169 **D1** D29 **D1** D169 D29 D85 12 **QUALITY OF LIFE** 10,1 10 8,9 **-22**% 7,8 PEAKS OF DRYNESS & ITCHING 8 **-57**% -64% 6,2 Mean QoL index With an average number of peaks of dryness and itching **-76**% -66% -65% in the 3 previous months **-82**%

# TOLERANCE

Tolerance was deemed **very good** by both dermatologist and pediatrician

1,6

DLQI

## ACCEPTABILITY

2,4

**IDQOL** 

97% of the subjects declared their skin comfortable & soothed

equal to 6.4 at D1, 87% of the

subjects did not report any

peak during the study.

## CONCLUSION

The efficacy results of this 6-month long clinical study demonstrate the benefits of this new emollient Plus in improving the long-term management of atopic skin condition. Moreover, its very good tolerance and acceptability by the patients could help to ensure long-term compliance.

-96%

0,\*2

**CDLQI**